NcXHF

SALVAGE CHEMOTHERAPY
References
1. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine,
and bleomycin combination chemotherapy in disseminated testicular
cancer. Ann Intern Med. 1977;87:293-298.
2. Williams SD, Einhorn LH, Greco FA, et al. VP-16-213 salvage therapy
for refractory germinal neoplasms. Cancer. 1980;46:2154-2158.
3. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ
cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
Ann Intern Med. 1988;109:540-546.
4. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide
plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
J Clin Oncol. 1998;16:2500-2504.
5. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel,
ifosfamide, and cisplatin is an effective second-line therapy for patients
with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23:6549-
6555.
6. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy
in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin
and etoposide with autologous bone marrow transplantation. J Clin Oncol.
1989;7:932-939.
7. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy
and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med.
2007;357:340-348.
8. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy
for patients with previously treated germ cell tumors: results
and prognostic factor analysis. J Clin Oncol. 2010;28:1706-1713.
9. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single highdose
chemotherapy in patients with relapsed or refractory germ cell tumors:
long-term results of a prospective randomized trial. J Clin Oncol.
2012;30:800-805.
10. International Prognostic Factors Study Group, Lorch A, Beyer J, et al.
Prognostic factors in patients with metastatic germ cell tumors who fail
cisplatin-based fırst-line chemotherapy. J Clin Oncol. 2010;28:4906-
4911.
11. Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus
high-dose chemotherapy as fırst salvage treatment in male patients with
metastatic germ cell tumors: evidence from a large international database.
J Clin Oncol. 2011;29:2178-2184.
12. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of
chemorefractory germ cell tumors. J Clin Oncol. 1993;11:324-329.
13. Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus
gemcitabine salvage chemotherapy for germ cell tumors after progression
following high-dose chemotherapy with tandem transplant. J Clin
Oncol. 2007;25:513-516.
14. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy
with gemcitabine plus oxaliplatin in patients with intensively pretreated
or refractory germ cell cancer: a study of the German Testicular
Cancer Study Group. J Clin Oncol. 2014;22:108-114.
15. Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy
with gemcitabine, oxaliplatin, and paclitaxel in patients with
cisplatin-refractory or multiply relapsed germ cell tumors: a study of the
Germ Testicular Cancer Study Group. Ann Oncol. 2008;19:448-453.
16. Feldman DR, Patil S, Trinos MJ, et al. Progression-free and overall survival
in patients with relapsed/refractory germ cell tumors treated with
single-agent chemotherapy: endpoints for clinical trial design. Cancer.
2012;118:981-986.
17. Miller J, Einhorn LH. Phase II study of daily oral etoposide in refractory
germ cell tumors. Semin Oncol. 1990;17:36-39.
18. Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes
in germ cell patients with very high human chorionic gonadotropin levels.
J Clin Oncol. 1998;16:1294-1297.
19. Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin
Oncol. 1995;13:1170-1176.
20. Hartmann JT, Einhorn L, Nichols CR, et al. Second-line chemotherapy
in patients with relapsed extragonadal nonseminomatous germ cell tumors:
results of an international multicenter analysis. J Clin Oncol. 2001;
19:1641-1648.
21. Radaideh SM, Cook VC, Kesler KA, et al. Outcome following resection
for patients with primary mediastinal nonseminomatous germ-cell tumors
and rising markers post- chemotherapy. Ann Oncol. 2010;21:804-
807.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e261